I. Introduction
Pondera has discovered an innovative method to simultaneously reduce respiratory and emotional distress. We have unlocked the calming potential of cAMP-PDE4 inhibitors — for years, seen as the “holy grail” for respiratory and psychiatric disorders, but has been elusive until now.
By reducing both respiratory and emotional distress, there is a remarkable synergy, which reverses the vicious cycle between them.
Over the course of three decades, our team of neuroscientists have discovered the key to unleashing the pain-relieving potential of exogenous and endogenous opioids. Now we have transferred this innovative methodology to the next generation medication for respiratory and anxiety disorders.
Section II. Publications
Section III. ENDORPHINATE®: Natural nutraceutical formulations that promote relief from emotional and physical distress by enhancing healthy endorphin functioning: calm + well-being + mental clarity + energy.
Pondera Endorphinate® Overview (PDF)
Pondera Endorphinate® Overview (MS Word)
Section IV. ROFLEX™: for the treatment of COPD exacerbations, asthma and respiratory disorders.
Pondera Roflex™ Overview (PDF)
Pondera Roflex™ Overview (MS Word)
Section V. Pondera patents.
- Pondera COPD/Asthma Patent (U.S. Patent No. 8,617,577, December 31, 2013) A method to safely and effectively treat asthma or chronic obstructive pulmonary disease in a subject in need comprising: (a) administering a Receptor Switcher to the subject, wherein the Receptor Switcher is naltrexone in an amount of about 1 microgram to about 500 micrograms; and (b) administering an Endorphin Enhancer, wherein the Endorphin Enhancer is selected from the group consisting of theophylline, roflumilast, ibudilast, cilomilast, zaprinast, rolipram, methylxanthine.
- Pondera Anxiety Disorder patent (U.S. Patent No. 8,741,319, June 3, 2013) A method to safely and effectively treat anxiety conditions, symptoms and/or disorders in a subject in need comprising: (a) administering a Receptor Switcher to the subject, wherein the Receptor Switcher is naltrexone; and (b) administering at least one Endorphin Enhancer to the subject, wherein the Endorphin Enhancer is roflumilast.
- Pondera Endorphinate Patent (US Patent No. 8,372,414; February 12, 2013)A method to safely and effectively treat Anxiety conditions, symptoms and/or disorders in a subject in need comprising: (a) administering at least one Receptor Switcher to the subject, wherein the receptor switcher is N-acetyl cysteine; and (b) administering at least one Endorphin Enhancer to the subject, wherein the endorphin enhancer is a compound comprising caffeine.